文献速递头痛与眩晕

阿托吉泮预防治疗偏头痛的早期改善:3项随机3期试验结果

Early Improvements With Atogepant for the Preventive Treatment of Migraine: Results From 3 Randomized Phase 3 Trials.
PubMed 文献 · Neurology · 2024-12-23

三项3期随机双盲安慰剂对照试验评估口服CGRP受体拮抗剂阿托吉泮60mg每日一次预防偏头痛的早期疗效。在发作性偏头痛和慢性偏头痛患者中,阿托吉泮在第1天即减少偏头痛日比例,并在第1-4周降低每周偏头痛天数、改善功能结局,优于安慰剂。

要点

  • 阿托吉泮60mg每日一次在第1天即显著降低出现偏头痛日的比例,三项试验的OR分别为0.39、0.53和0.63。
  • 阿托吉泮在第1-4周降低每周偏头痛天数,并在第1-4周改善AIM-D和EQ-5D-5L评分。
  • 三项试验中两项为发作性偏头痛,一项为慢性偏头痛,结果均显示阿托吉泮优于安慰剂。

核心结论

  • 阿托吉泮60mg每日一次在3项预防性研究中(2项发作性偏头痛和1项慢性偏头痛)于治疗前4周在疗效和功能指标上优于安慰剂。
  • 该研究提供II级证据表明阿托吉泮60mg每日一次在发作性偏头痛和慢性偏头痛患者中开始治疗4周内减少偏头痛频率并改善功能结局。

研究设计与样本

  • ADVANCE、ELEVATE和PROGRESS均为3期、多中心、随机、双盲、安慰剂对照的12周试验。
  • ADVANCE和ELEVATE纳入18-80岁、有超过1年发作性偏头痛病史且每月偏头痛天数4-14天的参与者;ELEVATE要求既往2-4类口服预防药治疗失败。
  • PROGRESS纳入18-80岁、有超过1年慢性偏头痛病史、每月头痛天数≥15天且每月偏头痛天数≥8天的参与者。
  • 本分析报告阿托吉泮60mg每日一次和安慰剂治疗组。
  • 改良意向治疗人群包括ADVANCE(阿托吉泮n=222;安慰剂n=214)、ELEVATE(阿托吉泮n=151;安慰剂n=154)和PROGRESS(阿托吉泮n=256;安慰剂n=246)。

主要发现

  • 第1天出现偏头痛日的比例:阿托吉泮组较安慰剂组降低,ADVANCE的OR为0.39(95%CI 0.23-0.67;p=0.0006),ELEVATE的OR为0.53(95%CI 0.29-0.94;p=0.031),PROGRESS的OR为0.63(95%CI 0.43-0.93;p=0.021)。
  • 阿托吉泮在第1-4周降低每周偏头痛天数,并在前4周降低每月偏头痛天数,与安慰剂相比。
  • 阿托吉泮在第1-4周所有评估时间点改善AIM-D和EQ-5D-5L评分,与安慰剂相比。

关键数值与推荐

  • 第1天出现偏头痛日的OR:ADVANCE 0.39(95%CI 0.23-0.67;p=0.0006),ELEVATE 0.53(95%CI 0.29-0.94;p=0.031),PROGRESS 0.63(95%CI 0.43-0.93;p=0.021)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Three phase 3 trials demonstrated the efficacy and safety of atogepant in episodic migraine (EM) and chronic migraine (CM) across 12-week treatment periods. This analysis evaluates improvements in efficacy and functional outcomes in the first 4 weeks of treatment with the oral calcitonin gene-related peptide receptor antagonist, atogepant, for the preventive treatment of migraine. METHODS: ADVANCE, ELEVATE, and PROGRESS were phase 3, multicenter, randomized, double-blind, placebo-controlled 12-week trials. ADVANCE and ELEVATE included participants aged 18-80 years with >1 year history of EM and 4-14 monthly migraine days (MMDs). ELEVATE required previous treatment failures to 2-4 classes of oral preventives. PROGRESS included participants aged 18-80 years with >1 year history of CM, ≥15 monthly headache days, and ≥8 MMDs. This analysis reports the atogepant 60 mg once daily (QD) and placebo treatment arms. Outcomes included efficacy endpoints (reporting a migraine day on day 1, change from baseline in weekly migraine days [WMDs] at weeks 1-4, and in MMDs in the first 4 weeks) and functional endpoints evaluated by the Activity Impairment in Migraine-Diary (AIM-D) at weeks 1-4 and the European Quality-of-Life 5-Dimension 5-Level (EQ-5D-5L) at weeks 1-2 and 4. RESULTS: The modified intent-to-treat population included the ADVANCE (atogepant, n = 222; placebo, n = 214), ELEVATE (atogepant, n = 151; placebo, n = 154), and PROGRESS (atogepant, n = 256; placebo, n = 246) studies. Atogepant-treated participants had greater reductions in the proportion of participants with a migraine day on day 1. The odds ratio compared with placebo was 0.39 (95% CI 0.23-0.67; p = 0.0006) in ADVANCE, 0.53 (95% CI 0.29-0.94, p = 0.031) in ELEVATE, and 0.63 (95% CI 0.43-0.93, p = 0.021) in PROGRESS. Atogepant treatment reduced WMDs at weeks 1-4 and MMDs in the first 4 weeks, and improved AIM-D and EQ-5D-5L at all assessed timepoints for weeks 1-4 compared with placebo. DISCUSSIONS: Atogepant 60 mg QD demonstrated superiority to placebo in efficacy and functional measures in the first 4 weeks of treatment across 3 preventive studies, 2 in EM and 1 in CM. TRIAL REGISTRATION: ClinicalTrials.gov NCT03777059; NCT04740827; NCT03855137. Submitted: 12/13/2018; 02/02/2021; 02/25/2019. First patient enrolled: 12/14/2018; 03/05/2021; 03/11/2019 clinicaltrials.gov/ct2/show/NCT03777059. clinicaltrials.gov/ct2/show/NCT04740827 clinicaltrials.gov/ct2/show/NCT03855137. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that atogepant 60 mg QD reduces migraine frequency and improves functional outcomes within 4 weeks of initiation in patients with EM and patients with CM.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Lipton RB, Gandhi P, Tassorelli C, et al. Early Improvements With Atogepant for the Preventive Treatment of Migraine: Results From 3 Randomized Phase 3 Trials. Neurology. 2024. PMID: 39715475. doi:10.1212/WNL.0000000000210212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。